PMC6260552_01
Significant neutrophilic engulfment in the cytoplasm of tumor cells with moderate pleomorphism (H.E., x200).
CRIONM2018-1301562.001.jpg
PMC6260552_01_CRIONM2018-1301562.001.jpg
fig1
The internalized neutrophils were intact (Figure 1).
Irregular tumor infiltration to the salivary gland in the resected sample. Significant diffuse neutrophilic infiltration in the tumor cells and surrounding stroma (H.E., x100).
CRIONM2018-1301562.002.jpg
PMC6260552_01_CRIONM2018-1301562.002.jpg
fig2
Some of the neutrophils in the tumor cells revealed degenerative changes by high-power field (x1000) microscopic evaluation (Figures 2-4), while some neutrophils included apoptotic bodies.
High-power field view of the marked area in Figure 2 (H.E., x400).
CRIONM2018-1301562.003.jpg
PMC6260552_01_CRIONM2018-1301562.003.jpg
fig3
Some of the neutrophils in the tumor cells revealed degenerative changes by high-power field (x1000) microscopic evaluation (Figures 2-4), while some neutrophils included apoptotic bodies.
Neutrophil aggregates in the cytoplasm of the tumor cells. Degenerative manifestations were evident and noticeable in some neutrophils. Nucleus of the tumor cell (big arrow) and nucleus of the engulfed neutrophils (small arrows) (H.E., x1000).
CRIONM2018-1301562.004.jpg
PMC6260552_01_CRIONM2018-1301562.004.jpg
fig4
Some of the neutrophils in the tumor cells revealed degenerative changes by high-power field (x1000) microscopic evaluation (Figures 2-4), while some neutrophils included apoptotic bodies.
Significant neutrophilic infiltration into the tumor cells and the background in the lymph node aspiration biopsy (PAP, x400).
CRIONM2018-1301562.005.jpg
PMC6260552_01_CRIONM2018-1301562.005.jpg
fig5
Tumor recurrence occurred in the periparotid and right neck lymph nodes after six months (Figure 5).
MR image of the solid tumor before pembrolizumab treatment.
CRIONM2018-1301562.006.jpg
PMC6260552_01_CRIONM2018-1301562.006.jpg
fig6
Following unresponsive chemotherapy, pembrolizumab treatment was started eight months prior to this study (Figure 6).
CT image of the rapidly growing tumor when the treatment was first interrupted.
CRIONM2018-1301562.007.jpg
PMC6260552_01_CRIONM2018-1301562.007.jpg
fig7
Pembrolizumab was interrupted and antituberculous treatment was started. Pembrolizumab was commenced when the tumor progressed to a 15 cm mass (Figure 7).
MR image of the tumor following pembrolizumab treatment: decreased tumor size revealing remission.
CRIONM2018-1301562.008.jpg
PMC6260552_01_CRIONM2018-1301562.008.jpg
fig8
Following the fourth dose of pembrolizumab, the tumor regressed to 4 cm (Figure 8) and the patient is currently alive for four years.